NCT00673673已完成2 期
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 2
- 主要终点
- Progression Free Survival
研究概览
简要总结
This is a Phase II open-label study to determine the anti-tumor efficacy and tolerability of FOLFOX in combination with bevacizumab (Avastin(TM))in patients with metastatic or unresectable gastroesophageal and gastric adenocarcinoma. Our primary objective is to determine the time to progression in patients treated with FOLFOX in combination with bevacizumab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically documented recurrent, metastatic or unresectable gastroesophageal (Siewert type I, II, III) or gastric adenocarcinoma with measurable or assessable non-measurable disease (RECIST criteria).
- •If recurrent or metastatic disease is not histologically confirmed, then documentation by a second radiographic procedure (i.e., PET scan or MRI in addition to CT scan) is required. If the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation is required
- •12 months since completion of any prior neoadjuvant or adjuvant therapy (chemotherapy or radiotherapy) for potentially resectable gastroesophageal or gastric adenocarcinoma.
- •>4 weeks since major surgery.
- •ECOG Performance Status: 0-1
- •Life expectancy >12 weeks
- •Laboratory parameters as follows: absolute neutrophil count ≥1,500/uL, platelet count ≥100,000/uL, hemoglobin ≥9 g,/dL, creatinine <1.5 X ULN or estimated GFR >30 ml's/min, urinalysis <2+ protein, baseline proteinuria <1000 mg/d or urine protein/creatinine ratio <1, bilirubin <2 X ULN, PT (INR) <1.5 if patient not on anticoagulation, negative pregnancy test in women of childbearing age
- •Hypertension must be well controlled (<160/90)
- •Paraffin block or slides must be available
- •Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of low molecular weight heparin.
排除标准
- •prior treatment for recurrent, metastatic, or unresectable gastroesophageal or gastric adenocarcinoma
- •other concurrent anticancer therapy
- •other malignancy within past three years except basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer known central nervous system metastases or carcinomatous meningitis.
- •interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung.
- •> grade 2 sensory peripheral neuropathy.
- •uncontrolled seizure disorder, active neurological disease, or known CNS disease.
- •significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment.
- •history of hypertensive crisis or hypertensive encephalopathy
- •abdominal fistula, gastrointestinal bleeding, or intra-abdominal abscess within the 6 months prior to study enrollment.
- •core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.
- •major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study.
- •recent arterial thrombotic events including stroke or TIA within 6 months prior to study enrollment.
- •serious or non-healing wound, ulcer or bone fracture.
- •active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices).
研究组 & 干预措施
1
Experimental
FOLFOX in combination with bevacizumab
干预措施: FOLFOX (Drug)
1
Experimental
FOLFOX in combination with bevacizumab
干预措施: bevacizumab (Drug)
结局指标
主要结局
Progression Free Survival
时间窗: Upon completion of study, up to 3 years
次要结局
- Overall Tumor Response Rate by RECIST Criteria(Upon completion of study)
- Overall Survival(Upon completion of study, up to 3 years)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerMetastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8NCT05627635City of Hope Medical Center20
已完成
2 期
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) PatientsMetastatic Breast CancerNCT01658033Fudan University72
进行中（未招募）
不适用
Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer - NDEUCTR2006-001779-39-ITAzienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
已完成
2 期
Bevacizumab And Combination Chemotherapy in Rectal Cancer Until SurgeryRectal CancerNCT01650428University College, London20
已完成
3 期
Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsMetastatic Colorectal CancerNCT01640405Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)350